UK Markets open in 3 hrs 30 mins

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
13.79-2.03 (-12.83%)
At close: 4:00PM EDT
13.79 0.00 (0.00%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close15.82
Bid13.74 x 800
Ask13.79 x 900
Day's range13.74 - 14.61
52-week range9.25 - 23.85
Avg. volume411,588
Market cap859.509M
Beta (5Y monthly)1.10
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Omeros Corporation Reports Second Quarter 2021 Financial Results

    SEATTLE, August 09, 2021--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced recent highlights and developments as well as financial results for the second quarter ended June 30,

  • Business Wire

    Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021

    SEATTLE, August 03, 2021--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021, on Monday, August 9, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

  • Business Wire

    Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association

    SEATTLE, Jun 14, 2021--Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) were shared during an oral presentation at the virtual edition of the 26th Congress of the European Hematology Association (EHA). The presentation, entitled Narsoplimab (OMS721) Treatment Contributes to Improvements in Organ Function in Adult P